The present invention provides compounds and herbicidal compositions comprising thereof. Further, use of herbicidal compositions or kit for controlling plant growth is also provided.

The present invention is a new tyrosine derivative described below to inhibit hydrolysis of polysulfide.

The new tyrosine derivative formed according to a chemical formula indicated below, wherein one of a-c is “OH” and the rest are “H”; d is C.sub.nH.sub.2nα, where α is “H” or a “halogen atom,” the halogen atom is preferably “I,” and n is an integer from 1 to 5; and e is (NH).sub.x(CO).sub.yC.sub.zH.sub.2zβ, where x is 1 or 0, y is 1 or 0, z is an integer from 1 to 5, β is “H” or a “halogen atom,”.

##STR00001##

The present invention is a new tyrosine derivative described below to inhibit hydrolysis of polysulfide.

The new tyrosine derivative formed according to a chemical formula indicated below, wherein one of a-c is “OH” and the rest are “H”; d is C.sub.nH.sub.2nα, where α is “H” or a “halogen atom,” the halogen atom is preferably “I,” and n is an integer from 1 to 5; and e is (NH).sub.x(CO).sub.yC.sub.zH.sub.2zβ, where x is 1 or 0, y is 1 or 0, z is an integer from 1 to 5, β is “H” or a “halogen atom,”.

##STR00001##

The present invention discloses a type-B crystal form of fenolamine, a preparation method thereof, and a composition and use thereof, more particularly a type-B crystal form of the fenolamine compound (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenylethyl)acrylamide, a preparation method thereof, and a composition and use thereof. Specifically, the present invention discloses the presence of a solid of a type-B fenolamine crystal form in solid state; a method for preparing the solid of type-B crystal form; and use of the solid of the type-B fenolamine crystal form as a pharmaceutical active ingredient in the manufacture of a medicament for prevention and treatment of Parkinson's disease (PD), improvement of learning and memory disorder, and treatment of memory loss and Alzheimer's disease (AD).

##STR00001##

The present invention discloses a type-B crystal form of fenolamine, a preparation method thereof, and a composition and use thereof, more particularly a type-B crystal form of the fenolamine compound (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenylethyl)acrylamide, a preparation method thereof, and a composition and use thereof. Specifically, the present invention discloses the presence of a solid of a type-B fenolamine crystal form in solid state; a method for preparing the solid of type-B crystal form; and use of the solid of the type-B fenolamine crystal form as a pharmaceutical active ingredient in the manufacture of a medicament for prevention and treatment of Parkinson's disease (PD), improvement of learning and memory disorder, and treatment of memory loss and Alzheimer's disease (AD). ##STR00001##

Processes and systems for producing N-vinyl carboxylic acid amides are provided herein. According to some aspects of the present invention, a process for producing an N-vinyl carboxylic acid amide is described that eliminates interim solids handling steps during formation of the intermediate compounds, thereby increasing efficiency and reducing cost. The processes and system described herein may be used for the synthesis of N-vinylformamide and its intermediates, including 1-hydroxyethylformamide and 1-alkoxyethylformamide, or for the synthesis of N-methyl,N-vinylformamide and its intermediates, including N-methyl,1-hydroxyethylformamide and N-methyl,1alkoxyethylformamide.

Processes and systems for producing N-vinyl carboxylic acid amides are provided herein. According to some aspects of the present invention, a process for producing an N-vinyl carboxylic acid amide is described that eliminates interim solids handling steps during formation of the intermediate compounds, thereby increasing efficiency and reducing cost. The processes and system described herein may be used for the synthesis of N-vinylformamide and its intermediates, including 1-hydroxyethylformamide and 1-alkoxyethylformamide, or for the synthesis of N-methyl,N-vinylformamide and its intermediates, including N-methyl,1-hydroxyethylformamide and N-methyl,1alkoxyethylformamide.

Processes and systems for producing N-vinyl carboxylic acid amides are provided herein. According to some aspects of the present invention, a process for producing an N-vinyl carboxylic acid amide is described that eliminates interim solids handling steps during formation of the intermediate compounds, thereby increasing efficiency and reducing cost. The processes and system described herein may be used for the synthesis of N-vinylformamide and its intermediates, including 1-hydroxyethylformamide and 1-alkoxyethylformamide, or for the synthesis of N-methyl,N-vinylformamide and its intermediates, including N-methyl,1-hydroxyethylformamide and N-methyl,1alkoxyethylformamide.

A compound has Structure I:

##STR00001##

where R.sub.1 and R.sub.2 independently are C.sub.2-C.sub.12 alkyl groups, R.sub.3 and R.sub.3 independently are H or CH.sub.3, X.sub.1 is a C.sub.4-C.sub.28 alkyl or alkenyl group, and R.sub.4 is H or a N,N-bis((meth)acryloylalkyl)-amide group having Structure II:

##STR00002##

where R.sub.5 and R.sub.6 independently are C.sub.2-C.sub.12 alkyl groups, and R.sub.3 and R.sub.3 independently are either H or CH.sub.3.

A compound has Structure I:

##STR00001##

where R.sub.1 and R.sub.2 independently are C.sub.2-C.sub.12 alkyl groups, R.sub.3 and R.sub.3 independently are H or CH.sub.3, X.sub.1 is a C.sub.4-C.sub.28 alkyl or alkenyl group, and R.sub.4 is H or a N,N-bis((meth)acryloylalkyl)-amide group having Structure II:

##STR00002##

where R.sub.5 and R.sub.6 independently are C.sub.2-C.sub.12 alkyl groups, and R.sub.3 and R.sub.3 independently are either H or CH.sub.3.